Sandip P. Patel, MD

Articles

Dr Patel on the Utility of the IPS Test in Solid Tumors

December 5th 2024

Sandip P. Patel, MD, discusses the Immune Profile Score and how it may be used to inform decisions with immune checkpoint inhibitor therapy in solid tumors.

FDA Approval Insights: Perioperative Durvalumab for Resectable NSCLC

October 3rd 2024

Drs Patel and Stiles discuss the significance of the FDA approval of perioperative durvalumab for patients with resectable non–small cell lung cancer.

Dr Patel on Areas of Advancement in the NSCLC Treatment Landscape

July 30th 2024

Sandip P. Patel, MD, discusses significant areas of advancements in the treatment paradigm for non–small cell lung cancer.

Dr Patel on the Exploration of Sacituzumab Govitecan in NSCLC

December 20th 2023

Sandip P. Patel, MD, discusses the utilization of sacituzumab govitecan in non–small cell lung cancer, highlighting trials in which the TROP2-directed antibody-drug conjugate is being evaluated in this patient population.

Ongoing Research on HER3-DXd in NSCLC

November 9th 2023

Ticiana Leal, MD, and Sandip P. Patel, MD, discuss clinical trials evaluating the use of patritumab deruxtecan in patients with non–small cell lung cancer and remaining unmet needs.

Role of HER3-DXd in Advanced NSCLC Treatment Landscape

November 2nd 2023

Clinical insights on where patritumab deruxtecan might fit in the treatment paradigm for patients with advanced non–small cell lung cancer.

NSCLC: Safety Outcomes from HERTHENA-Lung01

November 2nd 2023

Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.

Dr Patel on the Importance of Real-World Data in Lung Cancer Treatment

October 26th 2023

Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the continued importance of replicating clinical trial approaches in the real-world setting.

HERTHENA-Lung01: Patritumab Deruxtecan in Advanced EGFR-Mutated NSCLC

October 26th 2023

Experts on lung cancer review key data from the HERTHENA-Lung01 study investigating patritumab deruxtecan (HER3-DXd) in patients with advanced EGFR-mutated NSCLC.

The Role of HER3 in Non–Small Cell Lung Cancer

October 26th 2023

A medical oncologist discusses the role of HER3 in the treatment of non–small cell lung cancer and provides an overview of the HERTHENA-Lung01 clinical trial.

Treatments and Unmet Needs for EGFR-Mutated NSCLC

October 19th 2023

Expert perspectives on unmet needs and therapies available for patients with EGFR-mutated non–small cell lung cancer.

EGFR-Mutated NSCLC: Treatment Options Following Progression on Osimertinib

October 19th 2023

Ticiana Leal, MD, gives a comprehensive overview of treatment options for patients with EGFR-mutated NSCLC who progress on osimertinib therapy.

Dr Patel on Establishing a Consensus for Lung Cancer Treatment

October 12th 2023

Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, highlighting the similarities and differences between treating lung cancer in community oncology settings vs academic medical center settings.

Treatment Options for EGFR-Mutated NSCLC Following Progression

October 12th 2023

Sandip P. Patel, MD, discusses treatment options available for patients with EGFR-mutated NSCLC who progress on EGFR TKIs and platinum-based chemotherapy.

Current Treatment Landscape for EGFR-Mutated NSCLC

October 12th 2023

Medical oncologists specializing in lung cancer give an overview of the current treatment landscape for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study

October 4th 2023

Sandip P. Patel, MD, reviews data from the preliminary results of the EVOKE-02 study investigating sacituzumab govitecan plus pembrolizumab in first-line metastatic non–small cell lung cancer.

PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC

November 25th 2020

Data from completed studies evaluating immunotherapy in lung cancer alone or in combination with chemotherapy show that a breakdown of populations by PD-L1 status and additional considerations such as toxicity profiles should guide treatment decisions.

Dr. Patel on the Role of Immunotherapy Combinations in Lung Cancer

November 2nd 2020

Sandip P. Patel, MD, discusses the role of immunotherapy combinations in lung cancer.

Dr. Patel on Primary and Adaptive Resistance to Immunotherapy in NSCLC

May 24th 2018

Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses primary and adaptive resistance to immunotherapy in non–small cell lung cancer (NSCLC).

Dr. Patel Discusses Impact of Immunotherapy on NSCLC

May 11th 2018

Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses the impact of immunotherapy on the treatment of patients with non–small cell lung cancer.